To evaluate the impact of ERK1/2 suppression on HCC cell growth, we treated HCC cell lines with the well‐established MEK/ERK1/2 inhibitor mirdametinib[34] and conducted western blot and cell proliferation assays. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.